Shares in psychedelic drug developer Compass Pathways are sliding today after it announced that it will slash its headcount by 30% and focus all its efforts on its treatment-resistant depre
Sage Therapeutics has launched another round of layoffs as it deals with the fallout of abandoning a key pipeline drug for Alzheimer's and Parkinson's disease.
The sweeping changes introduced by new BioMarin chief executive Alexander Hardy continue apace, with a second round of layoffs that will cut another 225 positions from its total headcount.
